FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer By Ogkologos - February 13, 2025 745 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CodeBreaK 300 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Datopotamab Deruxtecan High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors MOST POPULAR Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 Hormone therapy gets green light for advanced prostate cancer September 14, 2021 EMA Recommends Extension of Indications for Sugemalimab October 28, 2025 Cancer clinical trials – learning lessons from the COVID-19 pandemic May 19, 2021 Load more HOT NEWS Cross-Border Network of European Specialists Provides New Treatment Options For Women... Elliot Colburn MP: Why Cancer Research UK’s Manifesto for Cancer Research... Pattern of DNA Damage Links Colorectal Cancer and Diet High in... Good-bye, Old Friend
